等待开盘 02-05 09:30:00 美东时间
+0.330
+3.67%
Tredegar Corporation Files Initial Beneficial Ownership Statement for Controller Paul Goldschmiedt Tredegar Corporation has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Paul Goldschmiedt, who serves as Controller at Tredegar, a
01-29 05:11
10% Owner James T. Gottwald Reports Disposal of Tredegar Corporation Common Shares James T. Gottwald, a 10% owner of Tredegar Corporation, has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Publi
01-22 05:35
10% Owner John D. Gottwald Reports Sale of Tredegar Corporation Common Shares John D. Gottwald, a 10% owner of Tredegar Corporation, has reported a disposal of common shares of Tredegar Corporation. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Pu
01-22 05:34
10% Owner William M. Gottwald Reports Disposal of Tredegar Corporation Common Shares William M. Gottwald, a 10% owner of Tredegar Corporation, reported a disposal of common shares of Tredegar Corporation. The full filing can be accessed through the link below. Disclaimer: This news brief was created
01-22 05:31
The latest announcement is out from Tredegar ( ($TG) ). On January 1, 2026, Tre...
01-07 21:44
An announcement from Tredegar ( ($TG) ) is now available. Tredegar Corporation ...
2025-11-21 06:26
Tredegar Corporation (NYSE:TG) today announced the retirement of John M. Steitz as its President and Chief Executive Officer and as a member of its Board of Directors (Board), effective December 31, 2025. The Board has
2025-11-21 05:49
Tredegar shares are trading higher after the company reported a year-over-year ...
2025-11-08 00:58
Tredegar (NYSE:TG) reported quarterly earnings of $0.26 per share. This is a 2500 percent increase over earnings of $0.01 per share from the same period last year. The company reported $162.470 million in sales this
2025-11-07 21:10
TG Therapeutics announced the completion of enrollment in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated dosing schedule for IV BRIUMVI in people with relapsing multiple sclerosis. The trial aims to assess non-inferior exposure compared to the existing regimen. BRIUMVI is currently approved for twice-yearly infusions and offers convenience among IV anti-CD20 treatments. TG plans to explore this simplified dosing regi...
2025-10-28 11:30